



Addressing unmet medical needs for patients living with
life-threatening diseases around the world



PURSU SCIENCE

To transform and simplify care

DISEASE
FOCUS

HIV/AIDS

INFLAMMATION AND RESPIRATORY

CARDIOVASCULAR

LIVER DISEASES

HEMATOLOGY AND ONCOLOGY



20+
marketed
products

Plus hundreds of ongoing and planned clinical studies help
Gilead address some of the world's largest health challenges

95-99%

Gilead's HCV medicines
offer cure* rates as high as
95-99% for all genotypes (1-6),
in less time, and with fewer side
effects than prior treatments

* Cure means the virus is undetected 3 months after
finishing treatment

NEARLY
30
YEARS

Gilead has been the
leader in transforming
HIV, making it a chronic
but manageable condition



ENABLING ACCESS

To medicine no matter
the person or place

TIERED
PRICING
+
GENERIC
LICENSING

A unique program **working to expand access** to
people in emerging and developing economies

10M

Patients on Gilead HIV
therapies in
developing countries



66%

Representing two-thirds
of those on treatment

1.5M

Patients worldwide treated with
Gilead HCV medicines

More than half of
these patients live in
developing countries



FOSTER COLLABORATION

To address the biggest
health challenges

Investing in partnerships and programs, we hope to achieve
more for patients than we could by working alone




**World Health
Organization**

**BILL & MELINDA
GATES foundation**



PEPFAR
U.S. President's Emergency Plan for AIDS Relief



3M

HIV tests given in the U.S. through
Gilead's FOCUS program

2016

#1

Gilead's rank among
corporate HIV/AIDS
philanthropic fundraisers

\$460M

Amount Gilead donated to
improve lives

2,000

Organizations that
received support

